Regulus and Alport Syndrome Foundation Raise Awareness of Life-Threatening, Genetic Kidney Disease

 Regulus and Alport Syndrome Foundation Raise Awareness of Life-Threatening,
                            Genetic Kidney Disease

PR Newswire

LA JOLLA, Calif., March 25, 2014

LA JOLLA, Calif., March 25, 2014 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, and the Alport
Syndrome Foundation ("ASF"), a non-profit corporation, announced today they
are working together to raise awareness of Alport Syndrome, a life-threatening
genetic kidney disease driven by genetic mutations with no approved therapy.

This month, Regulus will join the Alport Syndrome Foundation in observing
National Kidney Month and the first ever Alport Syndrome Awareness Month. As
part of that effort, Regulus hosted an Alport Syndrome awareness day at
Regulus' corporate headquarters in San Diego, CA. Alport Syndrome patients
Sharon Lagas and Ryan Landwehr were invited to provide Regulus employees with
patient perspectives on the impacts of living with Alport Syndrome.
Additionally, Regulus will serve as a Spirit of Action sponsor of the Alport
Syndrome Foundation 5K for Healthy Kidneys on Sunday, March 30^th, 2014 in
Tempe, Arizona. For more information, please
http://www.alportsyndrome.org/how-can-i-help/fundraising-new#awareness.

"We are grateful for the support from Regulus and know that it will take
patients working with companies like Regulus to advance the search for
potential Alport Syndrome treatment options," said Sharon Lagas, President of
the Alport Syndrome Foundation.

"Partnerships are critical to advancing scientific research for orphan
diseases such as Alport Syndrome," said Kleanthis G. Xanthopoulos, Ph.D.,
President and CEO of Regulus. "We are hopeful that our relationship with the
Alport Syndrome Foundation will advance our understanding of the disease and
believe that ASF will serve as an invaluable resource to us as we develop
RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport
Syndrome. We are excited to initiate a natural history of disease study for
RG-012 in the third quarter this year and expect to initiate a Phase I
clinical study of RG-012 in the first half of 2015."

Alport Syndrome is a genetic condition caused by mutations in the COL4A3,
COL4A4 or COL4A5 genes which impacts the body's ability to create a specific
type of collagen highly expressed in the kidney and essential to normal kidney
structure. In the absence of this type of collagen, the kidneys are unable to
effectively filter toxins and waste products, resulting in end-stage renal
disease. Lack of this special type of collagen can also result in hearing loss
or effects on vision. Alport Syndrome is considered an orphan disease with no
approved therapy.

Regulus is currently developing an innovative new therapy for the treatment of
Alport Syndrome. The company recently nominated a microRNA candidate to enter
clinical development, RG-012, an anti-miR targeting microRNA-21 ("miR-21") for
the treatment of Alport Syndrome. Preclinical studies have demonstrated that
RG-012 is a potent inhibitor of miR-21 in both in vitro and in vivo models and
that subcutaneous administration of RG-012 has significantly decreased the
rate of renal fibrosis and increased the lifespan of the mice in the studies
up to 50%. RG-012 has been well tolerated to date with a favorable
pharmacokinetic profile that supports the potential for a once/week dosing
regimen.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting
microRNAs.Regulus is uniquely positioned to leverage a mature therapeutic
platform that harnesses the oligonucleotide drug discovery and development
expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.,
which founded the company. Regulus has a well-balanced microRNA therapeutic
pipeline entering clinical development, an emerging microRNA biomarkers
platform to support its therapeutic programs, and a rich intellectual property
estate to retain its leadership in the microRNA field. Regulus intends to
focus its proprietary efforts on developing microRNA therapeutics for oncology
indications and orphan diseases and is currently advancing several programs
toward clinical development in oncology, fibrosis and metabolic diseases.
Specifically, Regulus is developing RG-012, an anti-miR targeting microRNA-21
for the treatment of Alport Syndrome, a life-threatening kidney disease driven
by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated
anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus
infection. Regulus' commitment to innovation and its leadership in the
microRNA field have enabled the formation of strategic alliances with
AstraZeneca, GlaxoSmithKline and Sanofi. In addition, the Company has
established Regulus microMarkers™, a research and development division focused
on identifying microRNAs as biomarkers of human disease, which is designed to
support its therapeutic pipeline, collaborators and strategic partners.

For more information, please visithttp://www.regulusrx.com.

About Alport Syndrome Foundation

The Alport Syndrome Foundation is an all-volunteer-led, non-profit
organization founded by a group of families affected by the disease and guided
by a Medical Advisory Committee of renowned Nephrologists. The Foundation was
built on the past efforts of the late Dr. Curtis Atkin (who himself had Alport
Syndrome) of the University of Utah and the Hereditary Nephritis Foundation.
ASF is the leading independent non-profit organization in the United States
serving and giving a voice to the Alport Syndrome community.

The ASF MISSION is to improve the lives of those affected by Alport Syndrome
through education, empowerment, advocacy, and funding research. The ASF VISION
is to make Alport Syndrome a treatable disease and ultimately find a cure.

For more information, please visit http://www.alportsyndrome.org/home/.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Website: http://www.regulusrx.com
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, aconrad@regulusrx.com, 858-202-6321, Media: Liz Bryan,
Spectrum Science, lbryan@spectrumscience.com, 202-955-6222 x2526
 
Press spacebar to pause and continue. Press esc to stop.